According to the Central Brain Tumor Registry of the United States (CBTRUS), in 2019, it is estimated that 86,970 new cases of primary malignant and non-malignant brain and other CNS tumors will be diagnosed in the United States. The majority will be diagnosed in adults with approximately 4,000 in children aged 0-14 years and 12,000 in adolescents and young adults aged 15-39 years. However, the majority of brain and other CNS tumors diagnosed in the United States are non-malignant primary brain tumors with over 60,000 diagnosed in 2019 and many more already living with these tumors. The most prevalent brain and other CNS tumor was glioblastoma in adults (aged 40 and older, 18,259 estimated living cases in 2010), pilocytic astrocytoma in children (aged 0-14, 4,177 estimated living cases in 2010), and in adolescents and young adults (aged 15-39, 6,215 estimated living cases in 2010).

This reinforces the American Brain Tumor Association’s commitment to increase research funding, improve the quality of information available to patients and caregivers; boost the number of newly diagnosed patients who get information they need right away, so they can make informed treatment decisions; and serve as the voice of the brain tumor community. These are all drivers for the ABTA to attend some of the nation’s leading oncology conferences, including the American Society of Clinical Oncology Annual Meeting, and provide the latest and most relevant information for the brain tumor community.

We are proud to bring you the MindMatters ASCO edition.

Thanks to the Central Brain Tumor Registry of the United States (CBTRUS) for contributing to this article.